Business
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program - - Platform presentation to feature data from ongoing Phase 1/2 trial of VRDN-001 - - Poster presentations to feature new clinical and preclinical research on VRDN-002 and VRDN-003 - WALTHAM, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that multiple abstracts featuring updates on the Company’s investigational therapies for the treatment of thyroid eye disease (TED)—including new preclinical research on VRDN-003—will be presented at the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO 2023), to be held April 23-27, 2023, in New Orleans, Louisiana. A platform session will feature the proof-of-concept results from the Phase 1/2 trial of VRDN-001 in patients with TED, while two posters will present new preclinical pharmacokinetic and bioavailability data on VRDN-002 as well as pharmacokinetic, pharmacodynamic, and safety data from healthy volunteers treated with VRDN-002. Two additional poster presentations will highlight the design, characterization, and preclinical pharmacokinetics of VRDN-003. VRDN-002 and VRDN-003 are next-generation, half-life extended antibody antagonists to the insulin-like growth factor-1 receptor (IGF-1R), in development for TED. Oral Presentation Data from Viridian’s ongoing Phase 1/2 clinical trial of VRDN-001 will be highlighted in an oral presentation on Thursday, April 27, 2023, from 2:15 to 2:30 pm CDT, during a session entitled “Eye Movement Disorders.” Poster Presentations Title:RDN-002, a Next-Generation Half-life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease: Safety and Pharmacokinetic/Pharmacodynamic (PK/PD) Results in Healthy VolunteersSession:Thyroid eye disease and extraocular musclesInformation:Wednesday, April 26, 2023, 10:30 am to 12:15 pm CDT, Poster #4038 - B0355 Title:Preclinical Pharmacokinetics and Bioavailability of VRDN-002, a Next-Generation Half-Life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye DiseaseSession:Thyroid eye disease and extraocular musclesInformation:Wednesday, April 26, 2023, 10:30 a...